CoChat
Sign Up
Cited by 26Extracellular vesicles in diseaseLiver Disease Diagnosis and TreatmentMesenchymal stem cell research

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Huc-MSCs-derived exosomes alleviate non-alcoholic steatohepatitis by regulating macrophages polarization through miR-24-3p/STING axis

Open access
Jiang, Wei, Zeng, Qingmin, Liu, Chang-Hai, Wang, Yonghong, Wang, Shisheng, Chen, Enqiang, Wang, Ming, Zhou, Taoyou, Bai, Lang, Wu, Dongbo, Tang, Hong·2025·Stem Cell Research & Therapy
DOI 10.1186/s13287-025-04197-6PMC PMC11846240
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: There's a scarcity of drugs effective against nonalcoholic steatohepatitis (NASH). Exosomes from Human umbilical cord mesenchymal stem cells (huc-MSCs) show potential in managing glycolipid metabolism and the immune response. Therefore, further investigations are required to explore their application in NASH and the underlying mechanisms. METHODS: C57BL/6J mice were fed with a western diet for 12 weeks to induce NASH, and huc-MSCs exosomes (MSCs-exo) were administered during the feeding period. The effect of MSCs-exo was evaluated by monitoring changes in body weight, fat distribution, blood glucose, and insulin levels, and analyzing pathological alterations in liver tissue. Mechanism investigations were carried out using flow cytometry, immunofluorescence staining, and other experimental techniques. RESULTS: MSCs-exo could reduce liver fat, inflammation, fibrosis, and improved metabolism to alleviate the progression of NASH. Besides, MSCs-exo could decrease macrophage accumulation in the liver, encouraging M2 over M1 macrophage polarization. Furthermore, our study found that MSCs-exo had a high expression of miR-24-3p, which may regulate macrophage polarization by targeting the interferon-stimulated genes (STING) gene in macrophages, with its overexpression amplifying MSCs-exo's NASH benefits. CONCLUSIONS: These findings suggest that the therapeutic effect of MSCs-exo on NASH may be attributed to the regulation of macrophage M2 polarization through miR-24-3p targeting STING. This provides a scientific basis for future clinical application.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13287-025-04197-6

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 MSCs-derived exosome (MSCs-Exo) relieve lipid deposition in NASH mice. A. Identification of multidirectional differentiation of MSCs. Adipogenesis differentiation ability was detected by oil red staining; Osteogenesis differentiation ability was detected by alizarin red staining; Hepatocyte-like differentiation ability was detected by glycogen staining; CD90 expression levels were examined by flow cytometry. B. Representative transmission electron microscopic images of hUC-MSCs-Exo; C. Western blot analysis of the surface hUC-MSCs-Exo markers CD9 and CD81. Full-length blots are presented in supplementary figure S3. D. Experimental workflow diagram for the treatment of NASH mice with MSCs-Exo. E and F. Glucose (mmol/L) and insulin (ng/ml) levels of mice in NC, WD and WDE. G. Hematoxylin & eosin (H&E) staining, Oil Red staining, Masson’s trichrome staining, and micro-CT imaging of liver tissues from NC, WD and WDE mice. The differences between groups were calculated using ANOVA (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001. Abbreviations: NASH, nonalcoholic steatohepatitis; MSCs, mesenchymal stem cells; Exo, exosome; NC, control group; WD, western diet group; WDE, exosome treatment group
Fig. 1 MSCs-derived exosome (MSCs-Exo) relieve lipid deposition in NASH mice. A. Identification of multidirectional differentiation of MSCs. Adipogenesis differentiation ability was detected by oil red staining; Osteogenesis differentiation ability was detected by alizarin red staining; Hepatocyte-like differentiation ability was detected by glycogen staining; CD90 expression levels were examined by flow cytometry. B. Representative transmission electron microscopic images of hUC-MSCs-Exo; C. Western blot analysis of the surface hUC-MSCs-Exo markers CD9 and CD81. Full-length blots are presented in supplementary figure S3. D. Experimental workflow diagram for the treatment of NASH mice with MSCs-Exo. E and F. Glucose (mmol/L) and insulin (ng/ml) levels of mice in NC, WD and WDE. G. Hematoxylin & eosin (H&E) staining, Oil Red staining, Masson’s trichrome staining, and micro-CT imaging of liver tissues from NC, WD and WDE mice. The differences between groups were calculated using ANOVA (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001. Abbreviations: NASH, nonalcoholic steatohepatitis; MSCs, mesenchymal stem cells; Exo, exosome; NC, control group; WD, western diet group; WDE, exosome treatment groupCC BY-NC-ND · PubMed Central
Fig. 2 Macrophages are involved in the pathogenesis of NASH. A. Immunofluorescence (IF) staining of CD68 in normal human liver samples and NASH patients’ liver samples. B. IF staining of F4/80 in the liver tissue of NC and WD mice. C. Flow cytometry analysis of F4/80+ and CD11b+ macrophages in the liver tissue of NC, WD mice. D. Quantitative analysis of F4/80+/CD11b+ in the liver tissue of NC, WD mice. E. Experimental workflow diagram for the treatment of NASH mice with MSCs-Exo, with or without macrophage scavenger (clodronate liposome). The clodronate liposome treatment group was named WDM. F, G. Glucose (mmol/L) and insulin (ng/ml) levels of mice in NC, WD and WDM. H. H&E staining, Oil Red staining, Masson’s trichrome staining, and micro-CT imaging of liver tissues from NC, WD and WDM mice. The differences between groups were calculated using ANOVA (n = 5). *p < 0.05. Abbreviations: NASH, nonalcoholic steatohepatitis; NC, control group; WD, western diet group; WDE, exosome treatment group
Fig. 2 Macrophages are involved in the pathogenesis of NASH. A. Immunofluorescence (IF) staining of CD68 in normal human liver samples and NASH patients’ liver samples. B. IF staining of F4/80 in the liver tissue of NC and WD mice. C. Flow cytometry analysis of F4/80+ and CD11b+ macrophages in the liver tissue of NC, WD mice. D. Quantitative analysis of F4/80+/CD11b+ in the liver tissue of NC, WD mice. E. Experimental workflow diagram for the treatment of NASH mice with MSCs-Exo, with or without macrophage scavenger (clodronate liposome). The clodronate liposome treatment group was named WDM. F, G. Glucose (mmol/L) and insulin (ng/ml) levels of mice in NC, WD and WDM. H. H&E staining, Oil Red staining, Masson’s trichrome staining, and micro-CT imaging of liver tissues from NC, WD and WDM mice. The differences between groups were calculated using ANOVA (n = 5). *p < 0.05. Abbreviations: NASH, nonalcoholic steatohepatitis; NC, control group; WD, western diet group; WDE, exosome treatment groupCC BY-NC-ND · PubMed Central
Fig. 3 MSCs-exo alleviate NASH by regulating macrophage function. A. IF staining of F4/80 in the liver tissue of NC, WD, and WDE mice. B. Flow cytometry analysis of F4/80+ and CD11b+ macrophages in the liver tissue of NC, WD, and WDE mice. C. Flow cytometry analysis of CD206− and CD11c+ macrophages in the liver tissue of NC, WD, and WDE mice. D and E. Quantitative analysis of CD206−/ CD11c+ and CD11c−/CD206+ in the liver tissue of NC, WD, and WDE mice. F. qRT-PCR analysis of the expression of TNF-α, IL-1β, Arg1, and CD206 in the liver tissue of NC, WD, and WDE mice. The differences between groups were calculated using ANOVA (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001. Abbreviations: NASH, nonalcoholic steatohepatitis; MSCs, mesenchymal stem cells; Exo, exosome; NC, control group; WD, western diet group; WDE, exosome treatment group
Fig. 3 MSCs-exo alleviate NASH by regulating macrophage function. A. IF staining of F4/80 in the liver tissue of NC, WD, and WDE mice. B. Flow cytometry analysis of F4/80+ and CD11b+ macrophages in the liver tissue of NC, WD, and WDE mice. C. Flow cytometry analysis of CD206− and CD11c+ macrophages in the liver tissue of NC, WD, and WDE mice. D and E. Quantitative analysis of CD206−/ CD11c+ and CD11c−/CD206+ in the liver tissue of NC, WD, and WDE mice. F. qRT-PCR analysis of the expression of TNF-α, IL-1β, Arg1, and CD206 in the liver tissue of NC, WD, and WDE mice. The differences between groups were calculated using ANOVA (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001. Abbreviations: NASH, nonalcoholic steatohepatitis; MSCs, mesenchymal stem cells; Exo, exosome; NC, control group; WD, western diet group; WDE, exosome treatment groupCC BY-NC-ND · PubMed Central
Fig. 4 MSCs-exo regulate macrophage polarity through the STING signaling pathway. A. Immunofluorescence co-localization of STING and CD68 in normal human liver samples and NASH patients. B. Immunofluorescence co-localization of STING and F4/80 of liver tissue from NC and WD mice. C. H&E staining, Oil Red staining, Masson’s trichrome staining, and micro-CT imaging of liver tissues from WD, WDD and WDED mice. D. Flow cytometry analysis of CD206− and CD11c+ macrophages in the liver tissue of WD, WDD and WDED mice. E and F. Quantitative analysis of CD206−/ CD11c+ and CD11c−/CD206+ in the liver tissue of WD, WDD and WDED mice. G. Western blot analysis of STING in the liver tissue of WD, WDD and WDED mice. Full-length blots are presented in supplementary figure S4. The differences between groups were calculated using ANOVA (n = 5). *p < 0.05. Abbreviations: MSCs, mesenchymal stem cells; Exo, exosome; NC, control group; WD, western diet group; WDE, exosome treatment group. WDD, STING agonist (DMXAA) treatment group; WDED, DMXAA and exosomes treatment group.
Fig. 4 MSCs-exo regulate macrophage polarity through the STING signaling pathway. A. Immunofluorescence co-localization of STING and CD68 in normal human liver samples and NASH patients. B. Immunofluorescence co-localization of STING and F4/80 of liver tissue from NC and WD mice. C. H&E staining, Oil Red staining, Masson’s trichrome staining, and micro-CT imaging of liver tissues from WD, WDD and WDED mice. D. Flow cytometry analysis of CD206− and CD11c+ macrophages in the liver tissue of WD, WDD and WDED mice. E and F. Quantitative analysis of CD206−/ CD11c+ and CD11c−/CD206+ in the liver tissue of WD, WDD and WDED mice. G. Western blot analysis of STING in the liver tissue of WD, WDD and WDED mice. Full-length blots are presented in supplementary figure S4. The differences between groups were calculated using ANOVA (n = 5). *p < 0.05. Abbreviations: MSCs, mesenchymal stem cells; Exo, exosome; NC, control group; WD, western diet group; WDE, exosome treatment group. WDD, STING agonist (DMXAA) treatment group; WDED, DMXAA and exosomes treatment group.CC BY-NC-ND · PubMed Central
Fig. 5 MSCs-exo carrying miR-24-3p regulate STING signaling pathway to alleviate NASH. A. qRT-PCR analysis of the expression of 9 miRNA candidates in the lysates from MSCs-Exo. B. Schematic diagram of the binding sites between miR-24-3p and wild-type STING 3’UTR (h-sting-3UTR-wt) or mutant (h-sting-3UTR-mu), and conservation analysis of the seed sequence. C. Luciferase reporter assays were used to confirm the combination between miR-24-3p and STING 3’UTR. D. H&E staining, Oil Red staining, Masson’s trichrome staining, and micro-CT imaging of liver tissues from WD, WDE and WDE-miR-24 mice. E. Flow cytometry analysis of CD206−, CD11c+ macrophages in the liver tissue of WD, WDE and WDE-miR-24 mice. F, G. Quantitative analysis of CD206−/ CD11c+ and CD11c−/CD206+ in the liver tissue of WD, WDE and WDE-miR-24 mice. H. Flow cytometry analysis of Arg1+ macrophages in the RAW of Ctrl, EVs, EVs + Agomir and EVs + Antagomir. I. Quantitative analysis of Arg1+ macrophages in the RAW of Ctrl, EVs, EVs + Agomir and EVs + Antagomir. The differences between groups were calculated using ANOVA (n = 5). *p < 0.05, **p < 0.01. Abbreviations: MSCs, mesenchymal stem cells; Exo, exosome; NC, control group; WD, western diet group; WDE, exosome treatment group. WDE, exosome treatment group; WDE-miR-24, miR-24-3p-rich exosomes treatment group
Fig. 5 MSCs-exo carrying miR-24-3p regulate STING signaling pathway to alleviate NASH. A. qRT-PCR analysis of the expression of 9 miRNA candidates in the lysates from MSCs-Exo. B. Schematic diagram of the binding sites between miR-24-3p and wild-type STING 3’UTR (h-sting-3UTR-wt) or mutant (h-sting-3UTR-mu), and conservation analysis of the seed sequence. C. Luciferase reporter assays were used to confirm the combination between miR-24-3p and STING 3’UTR. D. H&E staining, Oil Red staining, Masson’s trichrome staining, and micro-CT imaging of liver tissues from WD, WDE and WDE-miR-24 mice. E. Flow cytometry analysis of CD206−, CD11c+ macrophages in the liver tissue of WD, WDE and WDE-miR-24 mice. F, G. Quantitative analysis of CD206−/ CD11c+ and CD11c−/CD206+ in the liver tissue of WD, WDE and WDE-miR-24 mice. H. Flow cytometry analysis of Arg1+ macrophages in the RAW of Ctrl, EVs, EVs + Agomir and EVs + Antagomir. I. Quantitative analysis of Arg1+ macrophages in the RAW of Ctrl, EVs, EVs + Agomir and EVs + Antagomir. The differences between groups were calculated using ANOVA (n = 5). *p < 0.05, **p < 0.01. Abbreviations: MSCs, mesenchymal stem cells; Exo, exosome; NC, control group; WD, western diet group; WDE, exosome treatment group. WDE, exosome treatment group; WDE-miR-24, miR-24-3p-rich exosomes treatment groupCC BY-NC-ND · PubMed Central
Fig. 6 The potential mechanism of mesenchymal stem cell-derived exosomes (MSCs-exo) in treating nonalcoholic steatohepatitis (NASH). Western diet can induce M1 polarization of macrophages in liver, release inflammatory factors, and promote the formation and progression of NASH. MSCs-exo can induce M2 polarization of macrophages, reduce the release of inflammatory factors, and alleviate the formation and progression of NASH. The mechanism may be that exosomes-derived miR-24-3p regulates STING signaling pathway in macrophages
Fig. 6 The potential mechanism of mesenchymal stem cell-derived exosomes (MSCs-exo) in treating nonalcoholic steatohepatitis (NASH). Western diet can induce M1 polarization of macrophages in liver, release inflammatory factors, and promote the formation and progression of NASH. MSCs-exo can induce M2 polarization of macrophages, reduce the release of inflammatory factors, and alleviate the formation and progression of NASH. The mechanism may be that exosomes-derived miR-24-3p regulates STING signaling pathway in macrophagesCC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 39

  1. Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet (London England). 2021;397:2212–24. · DOI · Paper page
  2. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases, Hepatology (Baltimore, Md.), 67 (2018) 328–357. · DOI · Paper page
  3. Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and resolution of inflammation in NASH, Nature reviews. Gastroenterol Hepatol. 2018;15:349–64.
  4. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908–22. · DOI · Paper page
  5. EASL-EASD-EASO. Clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–402. · DOI · Paper page
  6. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention, Nature reviews. Gastroenterol Hepatol. 2021;18:223–38.
  7. Wang YH, Wu DB, Chen B, Chen EQ, Tang H. Progress in mesenchymal stem cell-based therapy for acute liver failure. Stem Cell Res Ther. 2018;9:227. · DOI
  8. Wu DB, Chen EQ, Tang H. Stem cell transplantation for the treatment of end-stage liver disease. World J Hepatol. 2018;10:907–10. · DOI
  9. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726–36. · DOI
  10. Qi Y, Ma J, Li S, Liu W. Applicability of adipose-derived mesenchymal stem cells in treatment of patients with type 2 diabetes. Stem Cell Res Ther. 2019;10:274. · DOI
  11. Liu X, Zheng P, Wang X, Dai G, Cheng H, Zhang Z, et al. A preliminary evaluation of efficacy and safety of Wharton’s jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus. Stem Cell Res Ther. 2014;5:57. · DOI
  12. Wang M, Song L, Strange C, Dong X, Wang H. Therapeutic effects of adipose stem cells from Diabetic mice for the treatment of type 2 diabetes. Mol Therapy: J Am Soc Gene Therapy. 2018;26:1921–30. · DOI
  13. Winkler S, Borkham-Kamphorst E, Stock P, Brückner S, Dollinger M, Weiskirchen R, et al. Human mesenchymal stem cells towards non-alcoholic steatohepatitis in an immunodeficient mouse model. Exp Cell Res. 2014;326:230–9. · DOI
  14. Yang Z, Xia Q, Lu D, Yue H, Zhang J, Li Y, et al. Human mesenchymal stem cells treatment improved hepatic lesions and reversed gut microbiome disorder in non-alcoholic steatohepatitis. Aging. 2020;12:21660–73. · DOI
  15. Phinney DG, Pittenger MF, Review C. MSC-Derived exosomes for cell-free therapy, stem cells (Dayton. Ohio). 2017;35:851–8.
  16. Mead B, Tomarev S. Bone marrow-derived mesenchymal stem cells-derived exosomes promote survival of retinal ganglion cells through miRNA-Dependent mechanisms. Stem Cells Translational Med. 2017;6:1273–85. · DOI
  17. Su T, Xiao Y, Xiao Y, Guo Q, Li C, Huang Y, et al. Bone marrow mesenchymal stem cells-derived exosomal MiR-29b-3p regulates Aging-Associated insulin resistance. ACS Nano. 2019;13:2450–62.
  18. Ha DH, Kim HK, Lee J, Kwon HH, Park GH, Yang SH et al. Mesenchymal Stem/Stromal Cell-Derived Exosomes for Immunomodulatory Therapeutics and Skin Regeneration, Cells, 9 (2020). · DOI
  19. Yagi H, Soto-Gutierrez A, Navarro-Alvarez N, Nahmias Y, Goldwasser Y, Kitagawa Y, et al. Reactive bone marrow stromal cells attenuate systemic inflammation via sTNFR1. Mol Therapy: J Am Soc Gene Therapy. 2010;18:1857–64. · DOI
  20. Nowacki M, Nazarewski Ł, Pokrywczyńska M, Kloskowski T, Tyloch D, Pietkun K, et al. Long-term influence of bone marrow-derived mesenchymal stem cells on liver ischemia-reperfusion injury in a rat model. Ann Transplant. 2015;20:132–40. · DOI
  21. Devi A, Pahuja I, Singh SP, Verma A, Bhattacharya D, Bhaskar A, et al. Revisiting the role of mesenchymal stem cells in tuberculosis and other infectious diseases. Cell Mol Immunol. 2023;20:600–12. · DOI
  22. Prakash N, Kim J, Jeon J, Kim S, Arai Y, Bello AB, et al. Progress and emerging techniques for biomaterial-based derivation of mesenchymal stem cells (MSCs) from pluripotent stem cells (PSCs). Biomaterials Res. 2023;27:31. · DOI · Paper page
  23. Shi H, Zhou K, Wang M, Wang N, Song Y, Xiong W, et al. Integrating physicomechanical and biological strategies for BTE: biomaterials-induced osteogenic differentiation of MSCs. Theranostics. 2023;13:3245–75. · DOI
  24. Wang M, Zhao N, Wang C, Jin ZB, Zhang L. Immunomodulatory properties of mesenchymal stem cells: a potential therapeutic strategy for allergic rhinitis. Allergy. 2023;78:1425–40. · DOI
  25. Yang X, Li Q, Liu W, Zong C, Wei L, Shi Y, et al. Mesenchymal stromal cells in hepatic fibrosis/cirrhosis: from pathogenesis to treatment. Cell Mol Immunol. 2023;20:583–99. · DOI · Paper page
  26. Ala M. The beneficial effects of mesenchymal stem cells and their exosomes on myocardial infarction and critical considerations for enhancing their efficacy. Ageing Res Rev. 2023;89:101980. · DOI
  27. Giovannelli L, Bari E, Jommi C, Tartara F, Armocida D, Garbossa D, et al. Mesenchymal stem cell secretome and extracellular vesicles for neurodegenerative diseases: risk-benefit profile and next steps for the market access. Bioactive Mater. 2023;29:16–35. · DOI · Paper page
  28. Wang C, Xu M, Fan Q, Li C, Zhou X. Therapeutic potential of exosome-based personalized delivery platform in chronic inflammatory diseases. Asian J Pharm Sci. 2023;18:100772.
  29. Sun Y, Shi H, Yin S, Ji C, Zhang X, Zhang B, et al. Human mesenchymal stem cell derived exosomes alleviate type 2 diabetes Mellitus by reversing Peripheral insulin resistance and relieving β-Cell Destruction. ACS Nano. 2018;12:7613–28. · DOI
  30. Tilg H, Moschen AR, Roden M. NAFLD and Diabetes Mellitus, Nature reviews. Gastroenterol Hepatol. 2017;14:32–42.
  31. Cai J, Zhang XJ, Li H. Role of Innate Immune Signaling in non-alcoholic fatty liver disease, trends in endocrinology and metabolism. Volume 29. TEM; 2018. pp. 712–22. · DOI
  32. Kazankov K, Jørgensen SMD, Thomsen KL, Møller HJ, Vilstrup H, George J, et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, Nature reviews. Gastroenterol Hepatol. 2019;16:145–59.
  33. Qiao JT, Cui C, Qing L, Wang LS, He TY, Yan F, et al. Activation of the STING-IRF3 pathway promotes hepatocyte inflammation, apoptosis and induces metabolic disorders in nonalcoholic fatty liver disease. Metab Clin Exp. 2018;81:13–24. · DOI
  34. Petrasek J, Iracheta-Vellve A, Csak T, Satishchandran A, Kodys K, Kurt-Jones EA, et al. STING-IRF3 pathway links endoplasmic reticulum stress with hepatocyte apoptosis in early alcoholic liver disease. Proc Natl Acad Sci USA. 2013;110:16544–9. · DOI
  35. Luo X, Li H, Ma L, Zhou J, Guo X, Woo SL et al. Expression of STING Is Increased in Liver Tissues From Patients With NAFLD and Promotes Macrophage-Mediated Hepatic Inflammation and Fibrosis in Mice, Gastroenterology, 155 (2018) 1971–1984.e4. · DOI · Paper page
  36. Yu Y, Liu Y, An W, Song J, Zhang Y, Zhao X. STING-mediated inflammation in Kupffer cells contributes to progression of nonalcoholic steatohepatitis. J Clin Investig. 2019;129:546–55. · DOI
  37. Fabian MR, Sonenberg N. The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nat Struct Mol Biol. 2012;19:586–93. · DOI
  38. Khan M, Harms JS, Liu Y, Eickhoff J, Tan JW, Hu T, et al. Brucella suppress STING expression via miR-24 to enhance infection. PLoS Pathog. 2020;16:e1009020. · DOI
  39. Xu T, Chu Q, Cui J. Rhabdovirus-Inducible MicroRNA-210 modulates antiviral innate Immune Response via Targeting STING/MITA in Fish. J Immunol (Baltimore Md: 1950). 2018;201:982–94. · DOI

Cited by

Sorted by citations

Metadata

Authors
Jiang, W., Zeng, Q., Liu, C.-H., Wang, Y., Wang, S., Chen, E., Wang, M., Zhou, T., Bai, L., Wu, D., & Tang, H.
Affiliations
Sichuan University (CN)
Corresponding author
  • Wu, Dongbo
  • Tang, Hong
ORCID
Venue
Stem Cell Research & Therapy
Publisher
Springer Science and Business Media LLC
Published
2025-02-21
Volume
16
Issue
1
Pages
74-74
ISSN
1757-6512 (ISSN-L)
DOI
10.1186/s13287-025-04197-6
PMC
PMC11846240
OpenAlex
W4407842915
Cited by
26
References
2
Citations by year
2026: 15 · 2025: 11
FWCI
7.82
Type
journal article
Language
en
Open access
Licence
Locations
  • Stem Cell Research & Therapy (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Key Research and Development Program of China (2022YFC2304800)
  • 1.35 project for disciplines of excellence, West China Hospital, Sichuan University (ZYGD23030)
  • National Natural Science Foundation of China (82172254, 81900512)
  • the Science and Technological Supports Project of Sichuan Province, China (2024NSFSC1690)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
Keywords
nonalcoholic steatohepatitis, exosomes, human umbilical cord mesenchymal stem cells, macrophage polarization, M2 macrophages, miR-24-3p, STING, liver fibrosis, liver inflammation, lipid metabolism
MeSH terms
STING Protein, Animals, Humans, Liver, Macrophages, Male, Membrane Proteins, Mice, Inbred C57BL, Umbilical Cord, MicroRNAs, Mice, Exosomes, Mesenchymal Stem Cells, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review